INDUCTION THERAPY for acute myeloid leukemia (AML) has been fairly standardized over the past two decades, with major controversies addressing the optimal postremission therapy. Nevertheless, whereas the most common induction therapy for AML consists of 3 days of an anthracycline, usually daunorubicin, and 7 days of cytarabine (3 + 7), many trials have been conducted in an attempt to improve this standard by introducing a more intensive combination with potential to improve the complete remission rate, remission duration, or the number of patients cured.

Modern therapy with AML begun some 30 years ago with the introduction of cytosine arabinoside1,2 and daunorubicin.3 With either of these single agents, 30% to 40% of adults attained a complete response and a small proportion of these patients were long-term survivors. Significant further improvement occurred with the introduction of combination chemotherapy for AML induction. For much of the past two decades, induction therapy has consisted of daunorubicin, cytarabine, and 6-thioguanine (DAT).4-8 Most investigators now have eliminated 6-thioguanine from the standard induction regimen because its inclusion was not shown to improve overall results.9,10 Although there is no single established induction regimen, the most widely used combination for treatment of newly diagnosed AML has been daunorubicin (the first available anthracycline3 ) at a dose of 45 mg/m2 intravenously for 3 days and cytarabine at a dose of 100 mg/m2 intravenously by continuous infusion for 7 days.11 This is the standard against which most new regimens are tested. With this regimen, between 50% and 75% of adult patients with AML achieve complete remission,12-14 but 25% to 40% of patients require more than one course of induction to achieve complete remission.14-17 A randomized study by the Cancer and Leukemia Group B (CALGB) established that reducing the dose of daunorubicin to 30 mg/m2 resulted in a lower response rate, particularly in adults less than 60 years of age.18 

Increasing the intensity of induction has generated considerable recent interest and such a strategy may be effective in at least two ways. First, because achieving complete remission is considered a sine qua non for prolonged disease-free survival, it is likely that any combination that alters the complete remission rate will affect the long-term outcome. Second, intensified induction therapy may affect the long-term survival without an apparent effect on the initial response rate. However, reports of improved disease-free survival attributable to intensified induction therapy need to be cautiously interpreted. Such benefit may be impossible to determine without regard to the choice of postremission therapy, much like the difficulty in evaluating the results of consolidation therapy without considering the type of induction. Finally, any strategy to intensify induction may lead to more profound myelosuppression and the potential for toxicity needs to be carefully considered. Such an approach may be associated with more severe treatment-related morbidity and mortality or, alternatively, toxicity may be less if fewer patients require more than one course of induction therapy.

Several studies have explored the benefits of amsacrine,19,20 aclarubicin,21,22 mitoxantrone,15 and idarubicin.23-27 Several well-conducted randomized trials showed that idarubicin,24-26 aclarubicin,22 and amsacrine20 may be superior to daunorubicin in younger adults. Furthermore, a randomized study suggested that mitoxantrone15 is at least as effective as daunorubicin. However, these agents have been compared with daunorubicin at a dose of 45 mg/m2. Notwithstanding theoretical advantages to the use of idarubicin,28-31 it is not clear that any observed improvement represents an inherent biologic advantage of a particular drug rather than biologic dose equivalence. There are no data to suggest that a higher dose of daunorubicin is more effective, because a prospective comparison of daunorubicin 45 mg/m2 versus 60 mg/m2 or higher has not been conducted. However, studies by the Southwest Oncology Group (SWOG) have reported a substantially better complete response rate with daunorubicin at a dose of 70 mg/m2 32 compared with 45 mg/m2.33 Although this was not a randomized comparison, these were sequential studies by the same cooperative group in which only the dose of daunorubicin varied. Randomized data comparing idarubicin with daunorubicin may illustrate this point. Whereas three randomized studies demonstrated an unequivocal or a trend towards improved results for idarubicin when compared with daunorubicin at 45 mg/m2, sequential studies by the Eastern Cooperative Oncology Group (ECOG) have shown that the complete response rate, achieved in more than 800 patients, with idarubicin at a dose of 12 mg/m2 was identical to the historical control in a similar number of patients that used 60 mg/m2 of daunorubicin.34 35 

Comparisons of dose intensity in AML are complicated by many factors such as patient age, antecedent myelodysplasia, supportive care, and patient selection. For example, a complete response rate of 81% achieved with 90 mg/m2 of daunorubicin has been reported.36 However, this study is not easily compared with other studies of AML in adults because the median age was only 31 years. Similarly, it is difficult to interpret the pilot study in which a higher dose of mitoxantrone (80 mg/m2 as a single bolus infusion) was tested in 20 patients yielding an 85% complete response rate.37 Although escalating the dose of induction appears beneficial in younger adults, data in older adults are conflicting. Some studies suggest that the increased regimen-related toxicity outweighs the clinical benefit.22,38 However, this has not been confirmed by others.11,39-41 Furthermore, some investigators have recommended against any dose attenuation of induction therapy.42 43 

Modifications in the dose and duration of cytarabine have also been addressed. Increasing the duration of cytarabine, from 7 to 10 days, has yielded, at best, modest improvement, particularly in younger adults.9,44 These CALGB trials showed that increasing the dose of cytarabine from 100 to 200 mg/m2/d did not lead to a significant improvement, and a randomized study evaluating a dose of 500 mg/m2 yielded similar results.45 However, administering cytarabine by continuous infusion was shown to be more effective than by bolus injection.11 Several prospective studies have compared induction regimens that modify both the dose of anthracycline and cytarabine.46,47 Therefore, meaningful interpretation is difficult. A regimen frequently used in Europe, consisting of mitoxantrone, etoposide, and cytarabine,48 has not been shown to be superior to standard induction therapy.

Cytarabine has also been used in induction in high doses (HDAC) since the initial report of its utility in refactory AML.49 Response rates as high as 90% have been reported with HDAC at doses of 1.5 to 3.0 g/m2 every 12 hours for 3 to 6 days.50-53 Most of these studies used HDAC either as a single agent52 or as a combination with either daunorubicin,53 amsacrine,51 or asparaginase.50 Toxicity was considereable; relatively small cohorts of patients were treated and the response rates were compared with historical controls. Only two randomized studies have directly compared HDAC with standard induction therapy while using the same postremission therapy in both arms.33 54 In contrast to earlier uncontrolled trials, these two studies reported that the complete response rate was not higher with HDAC than with standard induction therapy and was associated with increased toxicity. However, both studies noted a significantly longer disease-free survival for those patients receiving HDAC in induction.

The concept that intensifying induction therapy may not improve the initial response rate but may affect the long-term outcome has also been shown in a prospective randomized study when etoposide was added to standard induction therapy.55 56 Although showing that dose intensity of induction therapy may affect the duration of remission in AML, it is not clear that the increased toxicity through more profound myelosuppression is advantageous given the possibility that a similar intensification might be safely added during postremission therapy.

An alternative approach, namely adding HDAC directly after the standard 3 + 7 induction, ie, on days 8 through 10, was recently reported.57 The principle supporting this strategy involves both an intensification of current existing regimen as well as the potential benefit of timed sequential chemotherapy.58-62 Although a high response rate was reported (89%), this result was compared with historical controls. Furthermore, this was a limited-institution study and the literature describing AML therapy is replete with very high response rates initally reported from such limited studies, which could not be reproduced in large cooperative group trials. For example, the initial superior response to cytarabine and amsacrine reported in induction63 or consolidation51 was not confirmed in large cooperative group settings.34 64 Nevertheless, this approach is intriguing and two cooperative groups are currently conducting phase II studies investigating this strategy.

Administering intensive chemotherapy immediately after initial induction may lead to an improved long-term outcome. There are data that suggest that, after initial intensive induction therapy, residual leukemic cells may be recruited into the cell cycle, making them more susceptible to cell cycle-specific agents such as cytarabine.60,61,65,66 Several phase II studies have suggested that a number of patients who receive one or two courses of chemotherapy at time of maximal recruitment (6 to 10 days after initial therapy) could have a prolonged disease-free survival without further therapy.50,58,59,67 Whether these results are due to the biologic recruitment of cell cycle-specific agents or whether this represents the most effective consolidation at the optimal period of minimal residual disease is unknown. However, administering a repeat course of induction shortly after completion of the first course has been tested and its toxicity is known, because approximately 25% to 40% of adult patients with AML require a second course of induction at day 11 through 14 after the start of induction chemotherapy.14-17 Therefore, an alternative method of intensification may be to administer a second course of induction therapy on days 10 through 14 to all patients, including those who achieve marrow hypoplasia. Such a concept appears effective in children,68 but has never been tested in adults, although several attempts at administering a repeat or second induction at intervals of 21 days have been successfully reported.69 

Hematopoietic growth factors have been shown to shorten the period of neutropenia after induction therapy for AML,70,71 and several studies have reported reduced morbidity.17,72-74 There are also promising preclinical data exploring the use of thrombopoietin to shorten the period of thrombocytopenia.75 The best clinical use of these cytokines has not yet been described. Despite the potential for reducing morbidity after myelosuppressive therapy, there are no data that more intensive therapy can be safely delivered with cytokine support.

The current standard for inducing complete remission in previously untreated adults with de novo AML remains an anthracycline and cytarabine. Although there are promising areas for clinical investigation, at the present time a new standard of care for induction therapy has not yet emerged. Although there appear to be better agents than 45 mg/m2 of daunorubicin, the optimal anthracycline and dose has yet to be described. Prospective studies should determine whether escalating the doses of anthracyclines will yield improved response rates. Similarly, the addition of intensive therapy to the current standard regimen, such as high-dose cytarabine or etoposide, although clearly affecting the long-term remission duration, has not been shown to significantly affect the long-term outcome by comparison with known published postremission therapies.14,16 Some of the potential future strategies are summarized in Table 1. With the current high response to induction therapy it is crucial to have prospective randomized studies to determine whether any of these maneuvers are significantly better than standard induction therapy followed by optimal postremission therapy. Single-arm phase II trials should be limited to carefully designed studies describing efficacy and toxicity in regimens involving usually not more than a single change from standard therapy. Cooperative groups have a major role in this regard and should help to define any modifications to current therapy. Unfortunately, at present, only a minority of adults with AML enter cooperative group trials.76 Improved accrual must be encouraged, allowing for more rapid generation of data. It is also important to design studies that can be completed within a reasonable time frame, thus stimulating patient and physician interest and leading to further accrual. With these efforts it is hoped that the next decade may clearly identify a better strategy for induction therapy in AML.

The authors thank Peter A. Cassileth, MD, for reviewing the manuscript and Federick R. Appelbaum, MD, for providing SWOG data.

Address reprint requests to Jacob M. Rowe, MD, University of Rochester Medical Center, 601 Elmwood Ave, Rochester, NY 14642.

1
Freireich
EJ
Arabinosyl cytosine: A 20 year update.
J Clin Oncol
5
1987
523
2
Coltman CA, Freireich EJ, Pendleton O, Bickers JN, Bodey GP, Hewlett JS, McCredie KB: Adult acute leukemia studies using cytarabine: Early Southwest Oncology Group trials. Med Pediatr Oncol 10:173, 1982 (suppl 1)
3
Weil M, Glidewell OJ, Jacquillat C, Levy R, Serpick AA, Wiernik PH, Cuttner J, Hoogstraten B, Wasserman L, Ellison RR, Gailani S, Brunner K, Silver RT, Rege VB, Cooper MR, Lowenstein L, Nissen NI, Haurani F, Blom J, Boiron M, Bernard J, Holland JF :Daunorubicin in the therapy of acute granulocytic leukemia. Cancer Res 33:921, 1973
4
Rees
JKH
Sandler
RM
Challener
J
Hayhoe
FGJ
Treatment of acute myeloid leukemia with triple cytotoxic regimen: DAT.
Br J Cancer
36
1977
770
5
Gale
RP
Cline
MJ
High remission rate in acute myelocytic leukemia.
Cancer
1
1977
497
6
Mandelli
F
De Lipsis
E
Gregnani
F
Martelli
M
Liso
V
Amadori
S
Daunomycin, cytosine arabinoside and 6-thioguanine (DAT) vs vincristine, cytosine arabinoside, and 6-thioguanine (VAT) in the induction treatment of acute nonlymphocyte leukemia: A randomized collaborative study.
Med Pediatr Oncol
4
1978
231
7
Arlin Z, Gee T, Fried J, Clarkson B: Rapid induction of remission in acute nonlymphocytic leukemia. Proc Am Assoc Cancer Res 20:112a, 1979 (abstr)
8
Wiernik
PH
Glidewell
OJ
Hoagland
HC
Brunner
KW
Spurr
CL
Cuttner
J
Silver
RT
Carey
RW
DelDuca
V
Kung
FH
Holland
A comparative trial of daunorubicin, cytosine arabinoside, and thioguanine, and a combination of the three agents for the treatment of acute myelocytic leukemia.
Med Pediatr Oncol
6
1979
261
9
Preisler
HD
Davis
RB
Kirshner
J
Dupre
E
Richards
F
Hoagland
HC
Kopel
S
Levy
RN
Carey
R
Schulman
P
Gottlieb
AJ
McIntyre
OR
Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: A Cancer and Leukemia Group B study.
Blood
69
1987
1441
10
Omura
GA
Vogler
WR
Lesante
J
Silberman
H
Knospe
W
Gordan
D
Jarrel
R
Treatment for acute myelogenous leukemia: Influence of three induction regimens and maintenance with chemotherapy or BCG immunotherapy.
Cancer
49
1982
1530
11
Rai
KR
Holland
JF
Glidewell
O
Weinberg
V
Brunner
K
Obrecht
JP
Preisler
HD
Nawabi
JW
Prager
D
Carey
RW
Cooper
MR
Haurani
F
Hutchinson
JL
Silver
RT
Falkson
G
Wiernik
P
Hoagland
HC
Bloomfield
CD
James
GW
Gottlieb
A
Ramanan
SV
Blomb
J
Nissen
N
Bank
A
Ellison
RR
Kung
F
Henry
P
McIntyre
OR
Kaan
SK
Treatment of acute myelocytic leukemia: A study of the Cancer and Leukemia Group B.
Blood
58
1981
1203
12
Preisler
HD
Anderson
K
Rai
K
Cuttner
J
Yates
J
DuPre
E
Holland
JF
The frequency of long-term remission in patients with acute myelogenous leukaemia treated with conventional maintenance chemotherapy: A study of 760 patients with a minimal follow-up time of 6 years.
Br J Haematol
71
1989
198
13
Bandini
G
Zuffa
E
Rosti
G
Battista
R
D'Emilio
E
Leoni
F
Ciolli
S
Barbui
T
Bassan
R
Todeschini
G
Perona
G
Scapoli
G
Mangoni
L
Morra
E
DiPeisco
U
Visani
G
Tura
S
Long-term outcome of adults with acute myelogenous leukemia: Results of a prospective randomized study of chemotherapy with a minimal follow-up of 7 years.
Br J Haematol
77
1991
486
14
Stone
RM
Mayer
RJ
Treatment of the newly diagnosed adult with de novo acute myeloid leukemia.
Hematol Oncol Clin North Am
7
1993
47
15
Arlin
Z
Case
DC
Moore
J
Wiernik
P
Feldman
E
Saletan
S
Desei
P
Sai
L
Cartwright
K
Randomized multi-center trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL).
Leukemia
4
1990
177
16
Mayer
RJ
Davis
RB
Schiffer
CA
Berk
DT
Powell
BL
Schulman
P
Omura
GA
Moore
JO
Mcintyre
OR
Frei
E
for the Cancer and Leukemia Group B
Intensive postremission chemotherapy in adults with acute myeloid leukemia.
N Engl J Med
331
1994
896
17
Rowe
JM
Andersen
J
Mazza
JJ
Paietta
E
Bennett
JM
Hayes
A
Oette
D
Wiernik
PH
Phase III randomized-placebo controlled study on granulocyte-macrophage colony stimulating factor (G-MCSF ) in adult patients (55-70 years) of acute myelogenous leukemia (AML). A study of the Eastern Cooperative Oncology Group (ECOG).
Blood
86
1995
257
18
Yates
J
Glidewell
OJ
Wiernik
P
Cooper
MR
Steinberg
D
Dosik
H
Levy
R
Hoaglend
AC
Henry
P
Gottlieb
A
Cornell
C
Berenberg
J
Hutchison
JL
Raich
P
Nissen
N
Ellison
RR
Frelick
R
James
GW
Falkson
G
Silver
RT
Haurani
F
Green
M
Henderson
E
Leon
L
Holland
JF
Cytosine arabinoside with daunorubicin or adriamycin therapy with acute myelocytic leukemia: A CALGB study.
Blood
60
1982
454
19
Legha
SS
Keating
MJ
McCredie
KB
Bodey
GP
Freireich
EJ
Evaluation of AMSA in previously treated patients with acute leukemia: Results of therapy in 109 adults.
Blood
60
1982
484
20
Berman
E
Arlin
ZA
Gaynor
J
Miller
W
Gee
T
Kempin
SJ
Mertelsmann
R
Andraeft
M
Reich
L
Nahmias
N
Clarkson
B
Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: Results of the L-16M protocol.
Leukemia
3
1989
115
21
Warrell
RP
Arlin
ZA
Kempin
SJ
Young
CW
Phase I-II evaluation of a new anthracycline antibiotic, aclacinomycin A, in adults with refractory leukemia.
Cancer Treat Rep
66
1982
1619
22
Hansen
OP
Pedersen-Bjergaard
J
Ellegaard
G
Brincker
H
Doesen
AM
Christen
BE
Drivsholm
A
Hippe
E
Jans
H
Jensen
KB
Killmann
SD
Jensen
MK
Karle
H
Laursen
B
Nielsen
JB
Nissen
NI
Thorling
K
Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients of acute myeloid leukemia: A Danish National Phase III Trial. For the Danish Society of Hematology Study Group on AML.
Leukemia
5
1991
510
23
Berman
E
Raymond
Z
Daghestani
A
Arlin
ZA
Gee
TS
Kempin
S
Hancock
C
Williams
L
Stevens
YW
Clarkson
BD
Young
C
4-Demethoxydaunorubicin (idarubicin) in combination with 1-β-D-Arabinofuranosylytosine in a treatment of relapsed or refractory acute leukemia.
Cancer Res
49
1989
477
24
Berman
E
Heller
G
Santorsa
J
McKenzie
S
Gee
T
Tempin
F
Gulati
S
Andreess
M
Kolitz
J
Gabrilove
J
Reich
L
Mayer
K
Keefe
D
Trainor
K
Schluger
A
Penenberg
D
Raymond
V
O'Reilly
R
Jhanwar
S
Young
C
Clarkson
B
Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia.
Blood
77
1991
1666
25
Vogler
WR
Velez-Garcia
E
Weiner
RS
Flaum
MA
Bartolucci
AA
Omura
GA
Gerber
MC
Banks
PL
A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Group.
J Clin Oncol
10
1992
1103
26
Wiernik
PH
Banks
PLC
Case
DC
Arlin
ZA
Periman
PO
Todd
MB
Ritch
TS
Enck
R
Weitberg
AB
Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia.
Blood
79
1992
313
27
Mandelli
F
Petti
MC
Ardia
A
Di Pietro
N
Di Raimondo
F
Ganzina
F
Falconi
E
Geraci
E
Ladogana
S
Latagliata
R
Malleo
C
Nobile
F
Petti
N
Rotoli
B
Specchia
G
Tabilio
A
Luigi
R
A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukemia. A multicentric study from the Italian Co-operative Group GIMEMA.
Eur J Cancer
27
1991
750
28
Berman
E
McBride
N
Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells.
Blood
79
1992
3267
29
Muller
MR
Lennartz
K
Boogen
C
Nowrousian
MR
Rajewsky
MF
Seeber
S
Cytotoxicity of adriamycin, idarubicin, and vincristine in acute myeloid leukemia: Chemosensitization by verapamil in relation to P-glycoprotein expression.
Ann Hematol
65
1992
206
30
Robert
J
Rigal-Huguet
F
Hurteloup
P
Comparitive pharamacokinetic study of idarubicin and daunorubicin in leukemia patients.
Hematol Oncol
10
1992
111
31
Petrini
M
Mattii
L
Valentini
P
Sabbatini
AR
Grassi
B
Grandi
M
Idarubicin is active on MDR cells: Evaluation of DNA synthesis inhibition on P388 cell lines.
Ann Hematol
67
1993
227
32
Hewlett
J
Kopecky
KJ
Head
D
Eyre
HJ
Elias
L
Kingsburg
L
Balcerzak
ST
Dabich
L
Hynes
H
Bickers
JN
Appelbaum
FR
A prospective evaluation of the roles of allogeneic marrow transplantation and low-dose monthly maintenance chemotherapy in a treatment for adult acute myelogenous leukemia (AML): A Southwest Oncology Group study.
Leukemia
9
1995
562
33
Weick
JK
Kopecky
TJ
Appelbaum
FR
Head
DR
Kingsbury
LL
Balcerzak
SP
Ickers
JN
Hynes
HE
Welborn
JL
Simon
SR
Grever
M
A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previosly untreated acute myeloid leukemia: A Southwest Oncology Group study.
Blood
88
1996
2841
34
Cassileth
PA
Lynch
E
Hines
JD
Oken
MM
Mazza
JJ
Bennett
JM
McGlave
PB
Edelstein
M
Harrington
DP
O'Connell
MJ
Varying intensitiy of postremission therapy in acute myeloid leukemia.
Blood
79
1992
1924
35
Cassileth P, Harrington D, Paietta E, Lazarus H, Appelbaum F, Blume K, Bennett J, Hurd D, Willman C, Slovak M, Wiernik P: Comparison of autologous bone marrow transplantation(AutoBMT) with high-dose cytarabine (HDAC) in adult acute myeloid leukemia (AML) in first remission (CR1): An ECOG Intergroup study. Proc Am Soc Clin Oncol 16:89a, 1997 (abstr)
36
Appelbaum
FR
Dahlberg
S
Thomas
ED
Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison.
Ann Intern Med
101
1984
581
37
Feldman
EJ
Alberts
TS
Arlin
Z
Ahmed
T
Mittelman
A
Baskind
P
Peng
YM
Baer
M
Plezia
P
Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
J Clin Oncol
10
1993
2002
38
Kahn
SB
Begg
CB
Maza
JJ
Bennett
JM
Bonner
H
Glick
JH
Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in a treatment for acute nonlymphocytic leukemia in the elderly.
J Clin Oncol
2
1984
865
39
Tilly
H
Castaigne
S
Bordessoule
D
Casassus
P
Le Prise
PY
Tertian
G
Desablens
BB
Henry-Amar
M
Degos
L
Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly.
J Clin Oncol
8
1990
272
40
Rees JKH: Chemotherapy of acute myeloid leukemia in UK: Past, present and future. Bone Marrow Transplant 4:110, 1989 (suppl 1)
41
Dutcher JP, Strauman JJ, Wiernik PH: Treatment of acute nonlymphocytic leukemia in patients older than 60 years of age. Blood 64:163a, 1984 (abstr, supp 1)
42
Büchner TH, Hiddemann W, Maschmeyer G, Ludwig G, Aul C, Lathan B, Lengffelder B, Sauerland MC, Heinecke A: AML in patients of 60+ years: Full versus reduced dose induction. Randomized study of the AMLCG. Blood 80:209a, 1992 (abstr, suppl 1)
43
Sebban
C
Archimbaud
E
Coiffier
B
Guyotat
D
Treille-Ritouet
D
Maupas
J
Fiere
D
Treatment of acute myeloid leukemia in elderly patients. A retrospective study.
Cancer
61
1988
227
44
Dillman
RO
Davis
RB
Green
MR
Weiss
RB
Gottlieb
AJ
Caplan
S
Kopel
S
Preisler
H
McIntyre
OR
Schiffer
C
A comparative study of two different doses of cytarabine for acute myeloid leukemia: A phase III trial of Cancer and Leukemia Group B.
Blood
78
1991
2520
45
Schiller
G
Gajewski
J
Mimers
S
Territo
M
Ho
W
Loc
M
Champlin
R
A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukemia.
Br J Haemetol
81
1992
170
46
Rees
JK
Gray
G
Wheatley
K
Dose intensification in acute myeloid leukemia: Great effectiveness at lower cost. Principal report of a Medical Research Council's AML 9 study.
Br J Haematol
94
1996
89
47
Feldman
E
Seiter
K
Damon
L
Linker
C
Rugo
H
Ries
C
Case
DC
Beer
M
Ahmed
P
The randomized trial of high-vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia.
Leukemia
11
1997
485
48
Archimbaud
E
Fenaux
P
Reiffers
J
Cordonnier
C
Leblond
V
Travade
P
Troussard
X
Tilly
H
Auzann
Cau G
Marie
JP
Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide and cytarabine for refractory acute myelogenous leukemia.
Leukemia
7
1993
372
49
Rudnick
S
Cadman
E
Capizzi
R
High-dose cytosine arabinoside (HDARAC) in refractory acute leukemia.
Cancer
44
1979
1189
50
Capizzi
RL
Poole
M
Coopler
MR
Richards
F
Stuart
JJ
Jackson
DV
White
DR
Spurr
CL
Hopkins
JO
Muss
HB
Treatment of poor risk acute leukemia with sequential high dose ara-c and asparaginase.
Blood
63
1984
694
51
Hines
JD
Mazza
JJ
Oken
MM
Bennett
JM
Adelstein
DJ
Keller
A
O'Connell
MJ
High-dose cytosine arabinoside and m-AMSA induction and consolidation in patients with de novo acute non-lymphocytic leukemia: A phase I pilot study of the Eastern Cooperative Oncology Group.
Semin Oncol
12
1985
117
52
Curtis
JE
Messner
HA
Minden
MD
Minkin
S
McCullocogh
EA
High dose cytosine arabinoside (ara-c) in the treatment of acute myelogenous leukemia: Contributions to outcome of clinical and laboratory attriibutes.
J Clin Oncol
5
1987
532
53
Phillips
GL
Reece
DE
Shepherd
JD
Barnett
MJ
Brown
RA
Frei-Lahr
DA
Klingemann
HG
Bolwell
BJ
Spinelli
JJ
Herzig
RH
Herzig
GP
High-dose cytarabine and daunorubicin induction and postremission chemothreapy for the treatment of acute myelogenous leukemia in adults.
Blood
77
1991
1429
54
Bishop
JS
Matthews
JP
Young
GA
Szer
J
Gillett
A
Joshua
D
Bradstock
K
Enno
A
Wolf
MM
Fox
R
Cobcroft
R
Herrmann
R
Van der Weyden
M
Lowenthal
RM
Page
F
Garson
M
Juneja
S
A randomized trial of high-dose cytarabine in induction in acute myeloid leukemia.
Blood
87
1996
1710
55
Bishop
JS
Lowenthel
R M
Joshua
D
Mattthews
JT
Todd
D
Cobcroft
R
Whiteside
MG
Kronenberg
H
Ma
D
Dodds
A
Herrmann
R
Szer
J
Wolf
MM
Young
G
Australian
Study Group
Etoposide in acute non-lymphocytic leukemia.
Blood
75
1990
27
56
Bishop
JS
Intensified therapy for acute myeloid leukemia.
N Engl J Med
331
1994
941
57
Mitus
AJ
Miller
KB
Schenkein
DP
Ryan
HF
Parsons
SK
Wheeler
C
Antin
JH
Improved survival for patients with an acute myelogenous leukemia.
J Clin Oncol
13
1995
560
58
Vaughan
WP
Carp
JE
Burke
PJ
Long chemotherapy-free remission after single-cycle timed-sequential chemotherapy for acute myelocytic leukemia.
Cancer
45
1980
859
59
Vaughan
WP
Carp
JE
Burke
PJ
Two-cycle timed-sequential chemotherapy for adult acute nonlymphocytic leukemia.
Blood
5
1984
975
60
Karp
JE
Burke
PJ
Enhancement of drug pshychotoxicity by recruitment of leukemic myeloblasts with humoral stimulation.
Cancer Res
36
1976
3600
61
Karp
JE
Donehower
RC
Dole
G
Burke
PJ
Correlation of drug-perturbed marrow cell growth kinetics and intracellular of 1-β-D-Furanosylcytosine metabolism with clinical response in adult acute myelogenous leukemia.
Blood
69
1987
1134
62
Murtens
ACM
Van Bekkum
DW
Hagenbeek
A
The BN acute myelocytic leukemia (BNML): A rat model for studying human myelocytic acute leukemia.
Leukemia
4
1990
244
63
Arlin
ZA
Ahmed
T
Mittelman
A
Feldman
E
Mehta
R
Weinstein
P
Rieber
E
Sullivan
P
Baskind
P
A new regimen of amsacrine with high-dose cytarabine is safe and effective therapy for acute leukemia.
J Clin Oncol
5
1987
371
64
Karanes C, Kopeckey KJ, Durie BGM, Grever MR: Increased risk of early death with high-dose Ara-C and m-AMSA compared to high-dose Ara-C alone or high-dose Ara-C and mitoxantrone in high risk nonlymphosytic leukemia. Proc Am Soc Clin Oncol 8:201a, 1989 (abstr)
65
Lampkin
B
Nagao
T
Mauer
A
Synchronization and recruitment in acute leukemia.
J Clin Invest
50
1971
2204
66
Lampkin
B
McWilliams
N
Mauer
A
Flessa
H
Hako
D
Fisher
V
Manipulation of the mitotic cycle in a treatment myelogenous leukemia.
Br J Haematol
32
1976
29
67
Burke
PJ
Karp
JE
Geller
RB
Vaughan
WP
Cures of leukemia with aggressive postremission treatment: An update of timed sequential therapy (Ac-D-Ac).
Leukemia
3
1989
692
68
Woods
WG
Kobrinsky
N
Buckley
JD
Lee
JW
Sanders
J
Neudorf
S
Gold
S
Barnard
DR
DeSwarte
J
Dusenbery
K
Kalousek
D
Arthur
DC
Lange
BJ
Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: A report from the Childrens Cancer Group.
Blood
67
1996
4979
69
Büchner T, Hiddemann W, Wörmann B, Löffler H, Maschmeyer, G, Hossfeld D, Ludwig WD, Nowrousian M, Aul C, Schaefer W, Sauerland C, Heinecke A: Long term effects of prolonged maintenance and of very early intensification chemotherapy in AML: Data from AMLCG. Leukemia 6:68, 1992 (suppl 2)
70
Schiffer
CA
Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia.
Blood
88
1996
3675
71
Rowe
JM
Liesveld
JL
Hematopoietic growth factors in acute leukemia.
Leukemia
11
1997
328
72
Ohno
R
Tomonaga
M
Kobayashi
T Kanamaru A
Shrakawa
S
Masaoka
T
Omine
M
Oh
H
Nomura
T
Sakai
Y
Hirano
M
Yokomaku
S
Nakayma
S
Yoshida
Y
Miura
AD
Morishima
Y
Dohy
H
Niho
Y
Hamajima
N
Takaku
F
Effect of granulocyte-colony stimulating factor after intentive induction therapy in relapsed or refractory acute leukemia.
N Engl J Med
323
1990
871
73
Büchner
T
Hiddemann
W
Koenigsmann
M
Zühlsdorf
M
Wörmann
B
Boeckmann
A
Freire
EA
Innig
G
Maschmeyer
G
Ludwig
WD
Sauerland
MC
Heineck
A
Schulz
G
Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse.
Blood
78
1991
1190
74
Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin J, Papa G, Noens L, Ho J, O'Brien C, Matcham J, Barge A: Results of a randomized, double-blind placebo controlled phase III study of filgrastim in remission induction and early consolidation therapy for adults with de-novo acute myeloid leukemia. Blood 86:267a, 1995 (abstr, suppl 1)
75
Kaushansky
K
Lok
S
Holly
RD
Broudy
VC
Lin
N
Bailey
MC
Forstron
JW
Buddle
MM
Oort
PJ
Hagen
FS
Promotion of megakaryocyte progenitor expansion and differentiation by the c-mpl ligand thrombopoietin.
Nature
369
1994
568
76
Benson
AB
Pregler
JP
Bean
JA
Rademaker
AW
Eshler
B
Anderson
K
Oncologists' reluctance to accrue patients on to clinical trials: Illinois Cancer Center Study.
J Clin Oncol
9
1991
2067
Sign in via your Institution